Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dociparstat sodium - Cantex Pharmaceuticals

Drug Profile

Dociparstat sodium - Cantex Pharmaceuticals

Alternative Names: CX-01; ODSH; PGX-100; PGX-ODSH-2013-AML-1

Latest Information Update: 30 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ParinGenix
  • Developer Cantex Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Heparins; Ischaemic heart disorder therapies; Polysaccharides
  • Mechanism of Action Cathepsin G inhibitors; Chemokine CXCL12 inhibitors; CXCR4 receptor antagonists; HMGB1 protein inhibitors; Leucocyte elastase inhibitors; P selectin inhibitors; Platelet factor 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Pancreatic cancer
  • Phase I Brain injuries
  • No development reported Lung cancer; Solid tumours
  • Discontinued Acute coronary syndromes; Chronic obstructive pulmonary disease; Myocardial infarction; Reperfusion injury; Thrombocytopenia

Most Recent Events

  • 27 Aug 2018 Dociparstat sodium - Cantex Pharmaceuticals receives Fast Track designation for Acute myeloid leukaemia [IV,Infusion] (Combination therapy, Newly diagnosed, In the elderly) in USA
  • 28 Jun 2018 No recent reports of development identified for clinical-Phase-Unknown development in Lung-cancer in USA (IV, Infusion)
  • 28 Jun 2018 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours(In adolescents, In children) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top